Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported business updates and updated its outlook for 2026. “We are excited to enter 2026, as we get closer to two potentially transformative readouts over the next 18 months for tibulizumab, starting with anticipated...

VANCOUVER, British Columbia--(BUSINESS WIRE)--lululemon athletica inc. (NASDAQ:LULU) today announced that the Company now expects net revenue and diluted earnings per share for the fourth quarter of fiscal 2025 to be toward the high end of the previously guided ranges of $3.500 billion to $3.585 billion and $4.66 to $4.76, respectively. There is no change to the Company’s previous guidance for gross margin, selling, general and administrative expenses, or the effective tax rate. Meghan Frank, C...

AKRON, Ohio--(BUSINESS WIRE)--B&W is scheduled to participate in the 28th Annual Needham Growth Conference, which is being held virtually on Friday, January 16, 2026....

PORTLAND, Maine--(BUSINESS WIRE)--WEX (NYSE: WEX) (“WEX” or the “Company”), the global commerce platform that simplifies the business of running a business, today announced changes to the composition and leadership of the Company’s Board of Directors (the “Board”) to further enhance the effectiveness of the Board’s oversight. For several years, the Board has been developing and executing a plan to support thoughtful renewal and an orderly transition of independent director leadership, helping t...

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc 2025-1 Class A 144A XS3031494068 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84354% Margin: 0.85% Total Rate: 4.69354% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total Amount...

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc Series 2024-1 Class F RegS XS2768183688 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84354% Margin: 5.8% Total Rate: 9.64354% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Emerging Markets AlphaDEX UCITS ETF 09.01.2026 FEM IE00B8X9NX34  325,002.00 USD  14,277,140.98   43.929  ...